Bailard Inc. Makes New $181,000 Investment in LENSAR, Inc. (NASDAQ:LNSR)

Bailard Inc. purchased a new stake in LENSAR, Inc. (NASDAQ:LNSR - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 20,256 shares of the company's stock, valued at approximately $181,000. Bailard Inc. owned approximately 0.17% of LENSAR at the end of the most recent reporting period.

Separately, Geode Capital Management LLC lifted its holdings in shares of LENSAR by 3.5% in the third quarter. Geode Capital Management LLC now owns 100,431 shares of the company's stock valued at $460,000 after purchasing an additional 3,423 shares in the last quarter. Institutional investors and hedge funds own 40.15% of the company's stock.

LENSAR Stock Up 8.7 %

Shares of NASDAQ:LNSR traded up $1.19 during trading on Friday, reaching $14.86. The stock had a trading volume of 95,679 shares, compared to its average volume of 108,618. The business has a fifty day moving average price of $10.15 and a 200-day moving average price of $7.43. The stock has a market cap of $175.18 million, a P/E ratio of -10.18 and a beta of 0.62. LENSAR, Inc. has a fifty-two week low of $2.67 and a fifty-two week high of $16.40.

LENSAR (NASDAQ:LNSR - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($1.61) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by ($1.40). The firm had revenue of $16.73 million during the quarter, compared to analyst estimates of $14.95 million. LENSAR had a negative net margin of 34.03% and a negative return on equity of 49.02%.

Remove Ads

Analyst Upgrades and Downgrades

Separately, Lake Street Capital upped their price target on shares of LENSAR from $12.00 to $16.00 and gave the company a "buy" rating in a report on Friday, February 28th.

LENSAR Company Profile

LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.